Q-omics provides the consensus-scored SAR1AP3 profile across patient tissues and cancer cell-line models. SAR1AP3 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, SAR1AP3 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, SAR1AP3 RNA expression shows 7,750 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight SKCM, COAD, and BRCA as cancer lineages where SAR1AP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SAR1AP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SAR1AP3 survival associations across molecular data types. SAR1AP3 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SAR1AP3 RNA expression–survival associations across cancer types. High SAR1AP3 expression shows unfavorable associations in SKCM, MESO, READ, PAAD and BRCA, but favorable associations in HNSC. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify SKCM as the clearest survival context for SAR1AP3 RNA expression.
This table summarizes SAR1AP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for SAR1AP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SAR1AP3 shows lower tumor expression in KIRC and higher tumor expression in COAD, UCEC and CHOL. The COAD box plot shows higher SAR1AP3 RNA expression in tumor versus normal tissue (log2 FC = +0.188, t-test p = .005).
This table shows molecular features associated with SAR1AP3 in patient tissues and cancer cell lines. In patient samples, SAR1AP3 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
